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A B S T R A C T
A liquid chromatography tandem mass spectrometry method was developed for quantifying ten cannabinoids in
oral fluid (OF). This method utilizes OF collected by the Quantisal™ device and concurrently quantifies can-
nabinol (CBN), cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC), 11-hydroxy-Δ9-THC (11-OH-THC), 11-nor-
9-carboxy-Δ9-THC (THC-COOH), 11-nor-9-carboxy-Δ9-THC glucuronide (THC-COOH-gluc), Δ9-THC glucuronide
(THC-gluc), cannabigerol (CBG), tetrahydrocannabiverin (THCV), and Δ9-tetrahydrocannabinolic acid A (THCA-
A). Solid phase extraction was optimized using Oasis Prime HLB 30mg 96-well plates. Cannabinoids were se-
parated by liquid chromatography over a BEH C18 column and detected by a Waters TQ-S micro tandem mass
spectrometer. The lower limits of quantification (LLOQ) were 0.4 ng/mL for CBN, CBD, THC, 11-OH-THC, THC-
gluc, and THCV; and 1.0 ng/mL for THC-COOH, THC-COOH-gluc, CBG and THCA-A. Linear ranges extended to
2000 ng/mL for THC and 200 ng/mL for all other analytes. Inter-day analytical bias and imprecision at three
levels of quality control (QC) was within±15%. Mean extraction efficiencies ranged from 26.0–98.8%.
Applicability of this method was tested using samples collected from individuals randomly assigned to smoke
either a joint containing<0.1%, 5.9%, or 13.4% THC content. This method was able to identify and calculate
the concentration of 6 of 10 cannabinoids validated in this method.
1. Introduction
The majority of the US population lives in a State where it is legal to
consume marijuana for medical or recreational purposes [1]. With in-
creasing prevelance of marijuana use, there are concerns about the
potential for marijuana to impair driving performance [2]. Epidemio-
logical findings based on motor vehicle crash reports have been in-
conclusive with regards to the extent that marijuana consumption in-
creases an individual's risk (odds ratio (OR)) of crashing [3]. Many of
the drivers included in the studies were often impaired through a
combination of marijuana and other drugs, such as alcohol, making it
harder to tease out the effects of THC alone on crash risk [4]. De-
pending on the inclusion/exclusion criteria, the OR of crashing ranged
from 2 to 14. Several studies have concluded, after adjusting for nu-
merous factors (age, other drugs, etc.), that the OR for increased crash
risk following use of marijuana was only moderately increased with an
OR of 1.2–1.4 [5,6].
The main psychoactive component of marijuana is Δ9-tetra-
hydrocannabinol (THC). Driving under the influence (DUI) of mar-
ijuana is known to impair tracking ability, attention, reaction time,
hand-eye coordination, and perception of time and distance in a dose
dependent manner [7,8]. Time to peak impairment after smoking
marijuana is variable, but is thought to be around 1 h post-smoking and
appears to be dependent on multiple factors including frequency of use
and smoking technique [4].
Unlike blood alcohol, currently there are no blood concentrations of
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THC (or metabolites) that society recognizes as causing impairment.
The lack of an established marker of marijuana impairment makes it
difficult to craft objective legislation for road safety. Most states with
per se driving laws can be separated into zero tolerance, very low tol-
erance (< 2 ng/mL THC), or low tolerance (< 5 ng/mL THC) limits in
whole blood. The difficulty in using a zero tolerance approach is that
some cannabinoids are present in chronic users blood for> 30 days
after abstaining [9]. Another difficulty with using blood specimens to
prosecute DUI suspects is the delay between the time of a traffic stop
and blood draw. Generally it takes about 1.5 h after a suspect is pulled
over to obtain a blood sample. In this timeframe THC concentrations
may decrease by as much as 90% [10]. These limitations with whole
blood specimens make the use of alternative matrices like oral fluid
attractive.
Oral fluid has clear advantages over whole blood because collection
is less-invasive and can be performed at the roadside immediately after
an individual is determined impaired. Currently, no significant asso-
ciation between oral fluid and whole blood cannabinoid concentrations
exist after smoking [11,12]. Oral fluid has demonstrated a temporal
association with cannabis intake suggesting it would make a better
matrix for assessing recent intake compared with whole blood or urine
[13].
Methods exist for extraction of cannabinoids from oral fluid using
the Quantisal device [14,15]. However, the goal of this manuscript is to
combine previous methods into a single extraction procedure without a
hydrolysis step that would allow for the quantification of the following
compounds by one method: THC, cannabidiol (CBD), cannabinol
(CBN), cannabigerol (CBG), Δ9-tetrahydrocannabinolic acid (THCA-A),
tetrahydrocannabiverin (THCV), 11-hydroxy-Δ9-THC (11-OH-THC), 11-
nor-9-carboxy-Δ9-THC (THC-COOH), 11-nor-9-carboxy-Δ9-THC-glucur-
onide (THC-COOH-gluc), and Δ9-THC-glucuronide (THC-gluc). This
assay will be useful for OF cannabinoid analysis in the establishment of
a cannabinoid concentration associated with driving impairment.
2. Material and methods
2.1. Chemicals, materials, and sample collection
Stock solutions containing 1mg/mL or 100 μg/mL of CBN, CBD,
THC, 11-OH-THC, THC-COOH, THC-COOH-gluc, CBG, THCV, THCA-A,
and the internal standards cannabidiol-D3, (−)-Δ9-THC-D3, cannabinol-
D3, (± )-11-hydroxy-Δ9-THC-D3, and (± )-11-nor-9-carboxy-Δ9-THC-
D3 were purchased from Cerilliant (Round Rock, TX, USA). THC-gluc
(10 μg/mL) was purchased from ElSohly Laboratories (Oxford, MS,
USA).
Oasis prime HLB (30mg) 96-well extraction plates were purchased
from Waters (Milford, MA, USA). Mass spectrometry grade methanol
(MeOH), acetonitrile (ACN), and formic acid were purchased from
Fisher Scientific (Hampton, NH, USA). Blank synthetic OF matrix used
to prepare calibrators and quality control specimens was purchased
from Immunalysis (Pomona, CA, USA). OF was collected with the
Quantisal™ device also from Immunalysis. Participants refrained from
food or drink for 10min, then the absorptive cellulose pad was placed
under their tongue until the indicator turned blue or 5min had passed.
The collection pad was then placed into the plastic collection device
containing 3mL of extraction/stabilization buffer. The extraction buffer
is supplied with the Quantisal™ device. The capped tube was placed at
room temperature for at least 4 h but not> 24 h. The pad was then
removed from the stem using fisherbrand standard serum filters (Fisher
Scientific) and decanted into nunc 3mL cryovials from Wheaton
(Millville, NJ, USA). The samples were then stored at 4 °C. Each sample
was weighed in attempt to derive a short sample correction factor be-
fore being analyzed within 2months of collection [16].
2.2. Preparation of standard solutions
Methanol calibrator solutions were prepared using class A glass
volumetric pipettes and glass volumetric flasks. A 100 μg/mL stock was
prepared from 1mg/mL stock solutions of 11-OH-THC, THC, CBD, CBN,
CBG, THC-V and THCA-A. A 10 μg/mL stock was prepared by adding
1mL of the 100 μg/mL stock plus 1mL of each 100 μg/mL solutions of
THC-COOH, THC-COOH-glucuronide and quantum satis (q.s.) to 10mL
with MeOH. A 1000 ng/mL stock was prepared from the 10 μg/mL
stock plus 1mL of the 10 μg/mL THC-glucuronide. The 100 ng/mL
stock was made from the 1000 ng/mL stock. Parallel dilutions were
made from the 100 ng/mL stock to make up the remaining 50, 20, 5 and
2 ng/mL stock solution. All stocks were aliquoted and stored at−20 °C
in amber glass bottles with a teflon lined screw caps. When spiked into
OF the calibrators correspond to seven levels of standard (0.4, 1, 4, 10,
20, 200, and 2000 ng/mL) in each batch of oral fluid samples for THC
and six levels of standard (0.4, 1, 4, 10, 20, and 200 ng/mL) for every
other analyte.
A 1000 ng/mL stock solution of deuterium labeled internal stan-
dards (IS) was made from CBD-D3, (−)-Δ9-THC-D3, CBN-D3, (± )-11-
hydroxy-Δ9-THC-D3, and (± )-11-nor-9-carboxy-Δ9-THC-D3 stock so-
lutions in methanol. A 100 ng/mL working IS solution was prepared
from the 1000 ng/mL stock solution in methanol. The working IS so-
lution was aliquotted into 20mL amber glass screw top vials with teflon
lined screw caps. The internal standard solutions were sealed with
parafilm between each use and stored at −20 °C.
2.3. Quality control materials
The blank matrix for calibrators and QCs (“synthetic OF”) is a
mixture of 1 part BSA (0.1% in PBS) with 3 parts extraction buffer.
Positive QC standard solutions of 300, 60, and 12 ng/mL were prepared
by parallel dilutions from a 1000 ng/mL stock in methanol made the
same as described for the calibrator solution except using stock solu-
tions from a different lot than the calibrators. Each solution was ali-
quoted into amber glass auto sampler vials, sealed with parafilm and
stored at −20 °C. The solutions correspond to three levels of QC at 60,
12, and 2.4 ng/mL when processed in synthetic OF. The lower level of
QC was chosen to reflect a low concentration that was closer to per se
cut off values adapted by several states [17]. QC results were reviewed
according to an absolute criteria of± 20% of target values.
2.4. Solid-phase extraction (SPE)
All calibrators and QCs were prepared by adding 50 μL of calibrator,
50 μL of working IS, followed by one mL of blank matrix to corre-
sponding borosilicate tubes. Subject specimens were treated in a similar
manner except methanol was substituted for the calibrator. Samples
were then acidified with 400 μL of 4% phosphoric acid. Samples were
vortexed briefly then contents were transferred to a well of a 96 well
Oasis Prime HLB C18 SPE plate. Samples were forced through the wells
using a positive pressure manifold on low pressure until all liquid was
pushed through. This took approximately five minutes to drip through.
Each well was washed with 500 μL of SPE wash buffer (25% MeOH with
5% ammonium hydroxide) twice under low pressure. The pressure was
switched to max flow for one minute following the second wash to push
any excess liquid through the well. Compounds of interest were eluted
into 750 μL glass inserts (Waters Corporation) with three successive
100 μL aliquots of 98% ACN with 2% formic acid for a total of 300 μL
eluant. Extracts were evaporated under nitrogen at 40 °C with gas flow
set to 70 psi for 30min. Dried extracts were reconstituted with 200 μL
of 50% ACN containing 0.1% formic acid. Plates were covered with a
silicone/PTFE treated, pre-slit cap mat and vortexed using the Fisher
Scientific Ana Multi-tube vortexer (Cat #: 02215450) on speed setting
of 4 for 5min. Plates were centrifuged at 1962 x g for 10min in Sorvall
legend XFR centrifuge (Thermo) and then transferred to the sample
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organizer for LC-MS/MS analysis.
2.5. Liquid chromatography
Chromatography was performed using a Waters Aquity i-class UPLC
system equipped with sample organizer, binary solvent manager, au-
tosampler, and a column oven (Waters Corporation). Separation of
analytes was achieved using a Waters 2.1× 50mm Acquity UPLC BEH
C18 column packed with 1.7 μm sized particles. The analytical column
was attached to a 2.1 mm×5mm ACQUITY UPLC BEH C18 VanGuard
Pre-column packed with 1.7 μm particle size to prevent column de-
gradation due to sample buildup. Guard columns were replaced after
every 1000 injections. The autosampler was set to 10 °C. The column
heater was set to 40 °C. A full-loop 10 μL injection was made for each
sample. Gradient elution was performed using a mobile phase A (MPA)
of 5mM ammonium formate buffer with 0.1% formic acid and a mobile
phase B (MPB) of acetonitrile with 0.1% formic acid at a constant flow
rate of 400 μL/min. The initial gradient conditions were 50% MPB, held
for 30 s, and then linearly increased to 90% MPB over 3.5min. The final
MPB concentration was maintained for 15 s, before returning to initial
conditions and holding for 45 s. The maximum pressure was set to
15,000 psi.
2.6. Mass spectrometry
The LC system was coupled to a Waters TQ-S-micro triple quadru-
pole mass spectrometer interfaced with an electrospray ionization (ESI)
probe. Negative ionization was used for THC-COOH-gluc. All other
compounds used positive ionization. The mass spectrometry transition
ions were collected using a scheduled multiple reaction monitoring
mode (MRM) with four separate time windows. The first time window
(TW) was collected in negative ion mode from 1.00 to 1.50min. The
subsequent windows were collected in positive ion mode from 1.51 to
2.59min for TW-2, 2.60 to 3.22min for TW-3, and 3.23 to 4.20min for
TW-4. The selected precursor and product ions, collision energy, re-
tention times and associated windows are displayed in Table 1. The
source temperature was set to 550 °C for both modes. The instrument
was controlled with Masslynx V4.1 SCN945 SCN960 software (Waters
Inc.) and peaks were processed using TargetLynxs XS. A representative
reconstructed chromatogram of all quantifier ions from a 20 ng/mL
calibrator is displayed in Fig. 1.
2.7. Method validation
Method validation was performed according to Clinical &
Laboratory Standards Institute (CLSI) 62-A guidance on liquid chro-
matography-mass spectrometry methods and included establishing
linearity, within-run and between-run precision, trueness and bias,
limits of detection, extraction recovery, interferences, and matrix ef-
fects.
2.7.1. Sensitivity, limits of detection, and quantification
The LLOQ was established as the lowest concentration that ex-
hibited acceptable trueness (< 20% bias) and precision (CV<20%),
n=6. It also must exhibit a signal-to-noise (S/N) ratio of at least 10
with a quantifier to qualifier ion ratio within 20% of mean calibrator
ratios and have a visibly acceptable peak shape. Analyte peak identi-
fication criteria included relative retention time 1.02 ± 0.02 and ion
ratio (± 20% of calibrators). Compounds without deuterated IS had to
have matching retention times to that of calibrators within± 0.1min.
2.7.2. Linearity, trueness and precision
The calibration curve to establish linear fit included six calibrators
(0.4, 1, 4, 10, 20, and 200 ng/mL) for all analytes and a seventh cali-
brator for THC that extends the analytical measuring interval to
2000 ng/mL. Each batch also included a double blank (standard
containing matrix only) and a zero (blank matrix with IS). Linearity was
investigated by calculating the regression using the least-squares with a
weighting factor of 1/x applied for each analyte. Linearity was estab-
lished with five sets of calibrators, which were required to quantify
within± 15%, except at the LLOQ, which was required to quantify
within± 20% of target concentration with precision (% CV) of< 20%.
Correlation coefficients (R2) were required to exceed 0.995.
2.7.3. Intra-day and inter-day imprecision and bias
The intra-day bias and imprecision were evaluated with 8 replicates
at three levels of QC concentrations on the same day. The bias was
determined by comparing the mean measured concentration of each
analyte with that of the target value and was expressed as a percentage
of the target concentration. Acceptable values were within 20% of the
target concentration for the bias and within 20% for the CV. QC values
for each analyte were reassigned based on the mean of the intra-day
concentrations.
The inter-day imprecision and bias were evaluated with 2 replicates
at three levels of QC over 10 days (n=20 for each level of QC). The
mean values for each level of QC were acceptable if the bias was within
20% of the intra-day concentration and imprecision was<20%.
2.7.4. Selectivity, interferences, extraction recovery, and matrix effects
Extraction efficiencies and matrix effects were determined for each
analyte at the lowest level of QC according to the three sample set
method proposed by Matuszewski et al. (n= 5 for each analyte set)
[18]. In set A, synthetic blank matrix was fortified with the low QC and
IS prior to SPE. In set B, synthetic blank matrix was fortified with low
QC and IS after SPE. In set C, elution solvent was fortified with low QC
and IS. Percent Extraction efficiency was calculated by dividing analyte
mean peak areas of set A by set B and multiplied by 100. The matrix
effect was calculated by dividing the analyte mean peak areas of set B
by set C and multiplied by 100 to express as a percentage.
Table 1
MRM parameters for cannabinoids in oral fluid.
Compound
name
Precursor ion
(m/z)
Product ion
(m/z)
DT (s) CE (V) RT (min) TW
THC-COOH-
gluc
519.1 192.9 0.110 −18 1.20 1
519.1 299.2 0.110 −38 1.20 1
519.1 343.2 0.110 −22 1.20 1
THC-gluc 491.2 193.1 0.040 34 1.71 2
491.2 315.3 0.040 20 1.71 2
11-OH-THC 331.1 193.1 0.040 22 2.22 2
331.1 201.1 0.040 24 2.22 2
THC-COOH 345.1 193.1 0.040 26 2.29 2
345.1 327.2 0.040 14 2.29 2
CBG 317.1 94.9 0.040 36 2.85 3
317.1 122.9 0.040 34 2.85 3
317.1 193.1 0.040 16 2.85 3
CBD 315.1 122.9 0.040 32 2.88 3
315.1 193.1 0.040 20 2.88 3
THC-V 287.1 122.9 0.040 32 2.88 3
287.1 165.1 0.040 24 2.88 3
CBN 311.1 195.1 0.035 24 3.35 4
311.1 223.1 0.035 16 3.35 4
THC 315.1 135.1 0.035 20 3.60 4
315.1 193.1 0.035 18 3.60 4
THCA-A 359.2 77.0 0.035 70 3.91 4
359.2 219.0 0.035 32 3.91 4
359.2 341.2 0.035 14 3.91 4
THC-COOH-D3 348.1 302.1 0.040 20 2.28 2
11-OH-THC-
D3
334.3 196.3 0.040 22 2.19 2
CBD-D3 318.2 196.1 0.040 18 2.87 3
CBN-D3 314.2 223.1 0.035 20 3.33 4
THC-D3 318.2 196.1 0.035 18 3.60 4
Boldface denotes quantifier ion.
DT dwell time, CE collision energy, RT retention time, TW time window.
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To demonstrate that the synthetic OF was a valid substitute for OF
specimens from humans, OF from 10 drug free (by self report) volun-
teers was collected and processed such that a one mL aliquot was for-
tified with low QC and IS, while another one mL aliquot was processed
unaltered (to demonstrated absence of cannabinoids). The percent bias
was calculated by dividing the difference between the averaged con-
centration of the low QC in human OF samples from the average con-
centration of low QC in blank matrix by the averaged concentration of
low QC in blank matrix. A qualitative assessment of matrix interference
was also performed by injecting each of the unspiked OF samples while
simultaneously infusing a calibrator solution containing 10 ng/mL of
each analyte [16,19]. See Fig. 2 for total ion chromatograms of the
blank OF samples.
Potential drug interferences were assessed by generating 5 pools of
10 different drugs belonging to opiates, benzodiazepines, and other
common drugs of abuse that could be present in a suspected DUI subject
(Supplemental Table 1). Superphysiological concentrations of the pools
of drugs were added to blank OF samples fortified with low QC.
Recovery of the QC within± 20% of expected concentration in the
presence of superphysiological concentrations of drug pools was re-
quired to demonstrate lack of interference.
2.7.5. Stability studies and carryover
Autosampler stability was assessed by comparing the average area
counts from the low QC to the area counts of an injection at 24 and 48 h
post-extraction. Acceptable stability was set at± 20% CV in area of a
1.25 ng/mL stock compared to the initial injection. Lack of carryover
was established by injecting a blank matrix fortified with IS im-
mediately after the highest calibrator and then comparing the area
counts to the same blank matrix with IS injected prior to the calibration
curve. The acceptable level of carryover was a set to< 20% increase in
area counts of the blank matrix following reinjection after the highest
calibrator.
2.8. Determination of cannabinoids in authentic oral fluid samples collected
from participants in the California Assembly Bill (AB) 266 study
Proof of applicability is demonstrated by evaluating the con-
centrations of cannabinoids in three participants enrolled in an
Institutional Review Board-approved study evaluating the effects of
inhaled cannabis containing either placebo (0.02%), 5.9% or 13.4%
THC by weight. Inclusion criteria for participation were individuals had
to be at a minimum an occasional user (≥3× per week), abstain from
marijuana use 48 h prior to testing, and have a valid drivers license.
Oral fluid samples were collected upon arrival to the laboratory which
was tested to demonstrate THC < 5 ng/mL using the Alere OF point of
care instrument. Individuals whose OF screened negative on the Alere
device then smoked a joint containing either placebo, 5.9%, or 13.4%
THC. Oral fluid was then collected 15, 90, 210, and 280min after
smoking and processed as described above. The complete study design
and detailed methods will be published after the target enrollment of
180 subjects is complete.
2.8.1. Dilution verification
Dilution integrity was evaluated by fortifying blank matrix (n=3)
to a final concentration of 4000 ng/mL and then diluting 1:10 (v/v)
with blank matrix. Samples were then processed as described. Dilution
integrity was maintained if specimens quantified within±20% of the
expected diluted concentration.
Fig. 1. Representative chromatogram for 20 ng/mL OF calibrator. Numbers correspond to the following compounds (1) THCCOOH-gluc, (2) THC-gluc, (3) 11-OH-
THC-d3, (4) 11-OH-THC, (5) THCCOOH-d3, (6) THCCOOH, (7) CBG, (8) CBD-d3, (9) CBD, (10) THC-V, (11) CBN-D3, (12) CBN, (13) THC-D3, (14) THC, and (15)
THCA-A. The y-axis was set to 1×106 counts per second for all compounds.
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3. Results
3.1.1. Sensitivity and linearity
The LLOQ, defined as the concentration with a CV<20% for the
bias and precision values, was 0.4 ng/mL for CBN, CBD, THC, 11-OH-
THC, THC-gluc, and THC-V (Table 2). The LLOQ was 1 ng/mL for THC-
COOH, THC-COOH-gluc, CBG, and THCA-A. The linear range was
demonstrated for each analyte from the LLOQ to 200 ng/mL
(CV<20%), except for THC where the upper limit was extended to
2000 ng/mL (Table 2). The R2 values with the 1/x weighting were ac-
ceptable for all cannabinoids (R2 > 0.995). Fig. 2 shows the chroma-
tography at the LLOQ isolated from synthetic oral fluid and the low QC
in native oral fluid.
3.1.2. Intra-day and inter-day precision and bias
The intra-day biases ranged from 85 to 103% with an imprecision
Fig. 2. Representative chromatograms for the quantifier transitions for THC-COOH-gluc, THC-gluc, THC-COOH, CBG, THC, and THCA-A in authentic drug free oral
sample (left column) and the same sample spiked with the low QC (right column). Middle column demonstrates the chromatography at the LLOQ for each compound
displayed in synthetic oral fluid. Values in graph correspond to maximal peak height of each compound.
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(CV)≤7% for the low, middle, and high levels of QC (n=8). The inter-
day biases ranged from 95 to 114% with an imprecision ≤15% for all
analytes in the low, middle, and high levels of QC (n=20 over 10 days)
(Table 3).
3.1.3. Matrix effects, extraction recovery, and interferences
A qualitative matrix effect study was performed by infusing a 10 ng/
mL calibrator solution during an injection of an extracted oral fluid
specimen from drug-free volunteers (n=10). There was no observable
ion suppression or enhancement across any of the analytes peaks in the
human oral fluid specimens (Fig. 3). Quantitative assessment of matrix
effects was performed by fortifying the human drug-free oral fluid
specimens with low QC and calculating the percent recovery to ex-
pected values established in the inter-day validation (Table 4). Accep-
table critera were set as a percent difference<20% from expected. No
matrix effect exceeding this criteria was observed in the human oral
fluid specimens when compared with the synthetic oral fluid used for
calibrators and controls.
Extraction efficiency was determined by comparing average peak
areas of extracted blank matrix samples fortified with low, mid, or high
QC divided by peak areas of blank matrix samples fortified post-ex-
traction with QC. All analytes had less than a 9% difference in extrac-
tion efficiency between any level of QC with a range of efficiencies from
26.0–98.8% (Table 5). Percent matrix bias were determined by com-
paring average peak areas of blank matrix samples fortified post-ex-
traction with low, mid, or high QC divided by neat solutions of QC. The
range of percent matrix bias was −37.6–23.7%. THCA-A observed the
worst ion suppression followed by THC-V (Table 5). THC-COOH ob-
served the greatest ion enhancement due to matrix effects observed to
be> 20% in the mid QC, whereas all other analytes had percent dif-
ferences< 20%. The THC-COOH internal standard compensated for the
matrix enhancement providing results within±20% of target values.
Interferences were assessed from five pools of ten drugs
(Supplemental Table 1) in blank OF fortified with low QC. The percent
bias for all cannabinoids ranged from−17.4–12.7% (Table 6). Thus, no
drugs that were tested caused any interference in calculating the low
QC concentration.
3.1.4. Autosampler stability, dilution integrity, and carry-over
The areas for all the compounds were within±20% upon reinjec-
tion at 24 h in the autosampler. The 48 h injection of samples had a
percent difference within 20% for CBN, CBD, THC, 11-OH-THC, THC-
COOH, and CBG, but a percent difference<28% for THC-gluc, THC-
COOH-gluc, THC-V, and THCA-A. In the 48 h reinjections, the internal
standards compensated for changes in area counts so quantitative re-
sults were within 20% of the initial values.
Dilution integrity was acceptable within± 20% of target con-
centrations for THC after diluting 1:10 with blank matrix. THC quan-
tified within 3.1% of expected concentrations.
There was no evidence of carry-over for any of the cannabinoids
following injection of a sample containing 2000 ng/mL.
3.1.5. Analysis of authentic oral fluid samples
Quantification of THC and related metabolites is part of a research
project that aims to establish the concentration of cannabinoids asso-
ciated with driving impairment following consumption of a low does
(5.9% THC), high dose (13.4% THC), or placebo (0.02% THC).
Participants have their OF samples collected prior to and immediately
after smoking one of the randomly assigned joints. The study is a
double-blinded approach, thus the laboratory is blinded to which par-
ticipants have smoked which kind of joint until the conclusion of the
study. To demonstrate proof of applicability, the laboratory was un-
blinded to identify the first three participants in this study that smoked
either the placebo, low or high dose joint.
The purpose of including data from three subjects who smoked
marijuana is to demonstrate the analytical method is capable of mea-
suring these compounds in specimens obtained from human volunteers,
and not to draw any conclusions regarding pharmacokinetics or de-
termining severity of impairment. One participant from each group had
their oral fluid samples assessed by this method with concentrations of
each cannabinoid listed in Table 7. The placebo joint participant had
detectable levels of CBN and THC following consumption. The low dose
and high dose particpants had detectable levels of CBN, THC, CBG,
THC-V, and THCA-A following consumption of the joint. CBD was de-
tected in the low dose participant immediately after smoking. THC was
also detected in the placebo participant prior to smoking the joint.
THCCOOH-gluc, THC-gluc, 11-OH-THC, and THCCOOH were not de-
tected in any of the oral fluid samples tested.
4. Discussion
This work expands upon the prior knowledge of working with OF
Table 2
Linearity for each cannabinoid in the method. Calibrators percent accuracy
range and average correlation coefficient (R2) were established during the
Inter-day validation (n= 10).
LLOQ (ng/
mL)
ULOQ (ng/
mL)
Calibrators %
accuracy range
Average R2
THC-COOH-
gluc
1.0 200 80–102 0.9990
THC-gluc 0.4 200 96–103 0.9977
11-OH-THC 0.4 200 93–112 0.9995
THC-COOH 1.0 200 96–103 0.9996
CBG 1.0 200 92–114 0.9986
CBD 0.4 200 93–110 0.9996
THC-V 0.4 200 89–122 0.9993
CBN 0.4 200 90–107 0.9994
THC 0.4 2000 85–116 0.9988
THCA-A 1.0 200 95–113 0.9982
Table 3
Intra- and Inter-day bias and precision for each level of QC.
Analyte Intra-day bias (%) Intra-day precision (%CV) Inter-day bias (%) Inter-day precision (% CV)
Low Mid High Low Mid High Low Mid High Low Mid High
THC-COOH-gluc 7 2 8 7 7 5 −14 2 −3 15 8 11
THC-gluc 2 0 1 2 2 2 −9 −2 0 5 5 7
11-OH-THC 4 1 3 4 4 2 0 0 −5 5 5 6
THC-COOH 5 1 2 3 3 4 −3 0 −1 3 5 4
CBG 15 11 10 4 4 4 0 0 −2 8 7 9
CBD 6 1 5 2 3 5 1 1 −4 7 4 6
THC-V 5 −3 2 3 2 5 5 4 −1 6 5 8
CBN 7 2 5 4 4 4 −3 −1 −5 6 7 6
THC 6 1 3 3 2 3 2 3 −1 6 4 6
THCA-A 14 14 7 6 6 5 −10 0 1 11 11 10
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collected in the Quantisal devices and LC-MS/MS methods [14,15] to
simultaneously quantify ten cannabinoids. The simplistic design of this
method was intentional to demonstrate feasibility in future use in
driving under the influence of cannabis testing. Various parameters
were optimized during method development. We evaluated multiple
SPE bed volumes (Waters Oasis Prime HLB μElution, 10mg, or 30mg
96-well plates), with multiple combinations of washing and elution
conditions (alkalinized, neutral, or acidified solvents, data not shown).
Additional LC columns evaluated included XSelect HSS C18 2.5 μm
beads 2.1 mm×150mm, XSelect HSS T3 2.5 μm beads
2.1 mm×75mm, and HSS PFP 1.8 μm beads 2.1mm×50mm using
either acidified methanol or acetonitrile based mobile phase buffers.
Electrospray ionization in positive and negative ion mode was com-
pleted on each analyte. Ultimately, each parameter described in the
method was selected based on largest peak area with highest signal to
noise, while providing sufficient chromatographic separation.
All analytes in this method had an inter-day analytical bias± 15%
Fig. 3. Qualitative matrix effect assessment of ten individually injected blank OF samples infused with a 10 ng/mL calibrator. All ten samples are overlaid on this
total ion chromatogram along with a calibrator to more easily identify expected peak retention times for each compound. Identical to Fig. 1 the peaks correspond to
the following compounds retention time (minutes) THCCOOH-gluc (1.20), THC-gluc (1.71), 11-OH-THC (2.22), THCCOOH (2.29), CBG (2.85), CBD (2.88), THC-V
(2.88), CBN (3.35), THC (3.60), and THCA-A (3.91).
Table 4
Quantitative matrix interferences between real OF
and synthetic OF.
% Bias
THC-COOH-gluc 17
THC-gluc 4
11-OH-THC 4
THC-COOH 9
CBG 10
CBD 0
THC-V 4
CBN 0
THC 9
THCA-A 20
Table 5
Mean extraction efficiency and percent matrix bias for cannabinoids extracted
from blank matrix by SPE.
% Extraction efficiency % Matrix bias
Low Mid High Low Mid High
THC-COOH-gluc 37.5 36.6 37.6 −4.1 5.9 3.6
THC-gluc 83.2 84.6 82.0 1.8 9.2 14.1
11-OH-THC-D3 87.2 87.8 84.1 14.5 19.9 16.9
11-OH-THC 82.0 84.6 81.2 14.3 19.9 16.4
THC-COOH-D3 64.7 63.5 62.9 17.4 23.7 19.8
THC-COOH 61.7 60.4 58.3 14.8 22.7 20.3
CBG 50.2 57.9 53.3 13.2 17.5 15.3
CBD-D3 87.3 94.3 90.5 −10.6 −8.8 −4.7
CBD 79.3 87.4 86.6 −11.4 −9.7 −4.4
THC-V 90.2 97.0 98.8 −32.6 −27.9 −18.2
CBN-D3 55.2 61.4 56.3 7.3 12.2 12.4
CBN 51.1 58.4 55.5 5.4 12.3 12.2
THC-D3 63.8 71.5 68.2 −11.7 −6.6 1.0
THC 60.2 67.2 63.1 −12.2 −5.2 −2.6
THCA-A 27.4 26.0 27.4 −37.6 −21.2 −21.7
Table 6
Drug interferences assessed by % Bias from interday assigned low QC values.
Blanka %
bias
Drug
pool 1%
bias
Drug
pool 2%
bias
Drug
pool 3%
bias
Drug
pool
4% bias
Drug
pool 5%
bias
THC-COOH-
gluc
−5.4 −8.3 −4.2 0.0 4.2 −12.5
THC-gluc −6.3 0.0 8.3 4.2 4.2 4.2
11-OH-THC −4.8 0.0 −4.5 0.0 9.1 0.0
THC-COOH 2.1 −16.7 −8.3 −4.2 −4.2 −8.3
CBG 12.7 −4.3 −17.4 −13.0 0.0 −8.7
CBD 3.6 −13.0 0.0 0.0 4.3 −8.7
THC-V 6.0 −8.7 −4.3 −4.3 0.0 −4.3
CBN 0.0 −8.7 −8.7 −4.3 0.0 4.3
THC −0.5 −4.5 0.0 −4.5 4.5 −4.5
THCA-A 1.7 −13.0 −8.7 −17.4 −4.3 0.0
a Denotes low QC fortified with methanol (vehicle).
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with an imprecision ≤15% CV. Extraction efficiencies and matrix ef-
fects were similar to previous studies [14,15]. The deuterated internal
standards accounted for any extraction or matrix effects allowing for
the quantification of analytes within±20%. Similar to Desrosiers et al.
[14], CBD-d3 was selected as the internal standard for THC-V and CBG,
since at the time of validation no deuterated internal standards were
available for these two compounds. A quantifier to qualifier ion ratio
flag was observed at 0.4 ng/mL for CBG resulting in an elevated LLOQ
for CBG to 1 ng/mL.
THC-d3 was employed as the deuterated internal standard for
THCA-A due to the closeness in retention time. THCA-A had the lowest
extraction efficiency and largest matrix effect of all the cannabinoids
tested. This is likely due to the adhesiveness of this molecule to glass
and plastics used throughout the procedure.
We did not detect 11-OH-THC, THCCOOH, THC-gluc or THCCOOH-
gluc in the first three participants of each group using this method.
However it does seem unlikely that glucuronidated molecules will be
present above those lower limits in oral fluid, since concentrations of
THC-gluc in blood following controlled cannabis smoking were <
1.1 ng/mL [20,21]. Negligible amounts of THC-gluc in OF has been
suggested by the lack of increased THC concentrations following glu-
curonidase treatment [22]. The lack of 11-OH-THC and THCCOOH in
OF collected using quantisal devices is not unexpected as other pub-
lished works have measured these analytes in the 0.01–0.35 ng/mL
range, which is below our LLOQ in this method [13,14]. Furthermore,
THCCOOH has been notoriously difficult to quantify using OF collected
from the quantisal device with most methods utilizing 2-dimensional
GC–MS or atmospheric pressure chemical ionization LC-MS/MS with a
enzymatic hydrolysis to enrich the THCCOOH pool [14,22–25]. The
inclusion of THCCOOH in OF was suggested to confirm direct inhala-
tion and help establish a limit to rule out passive exposure [25,26].
However, due to the analytical difficulties of measuring to such a small
concentration THCCOOH is likely to be only useful to rule in con-
sumption with a negative result unable to accurately rule out.
We included THC-V, CBG, and THCA-A in this method to in-
corporate as many available cannabinoid markers as possible since this
method will be used to support pharmacokinetic and pharmacody-
namics studies of marijuana use. This method differs from previous
methods measuring cannabinoids in OF after solid phase extraction
such that this method quantifies 10 cannabinoids, whereas others have
measured 6–8 in one method [14,15].
5. Conclusions
This LC-MS/MS method expands upon previous methods by quan-
tifying 10 cannabinoids in OF with a LLOQ of 0.4 ng/mL for THC, CBN,
11-OH-THC, CBD, THC-V and THC-glucuronide, and 1.0 ng/mL for
THC-COOH, THC-COOH-glucuronide, CBG, and THCA-A. The main
advantages of this method include the utilization of a simplified sample
preparation procedure and its validation over a clinicaly relevant ana-
lytical measurement range of concentrations for each cannabinoid.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.cca.2019.01.002.
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